Position in ELVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$7,612,500
+$3,518,500 QoQ
Shares Held
150,000
-25.0% QoQ
Ownership
0.205%
of shares outstanding
% of Portfolio
0.39%
of 13F equity value
Holder Rank
#66
of 210 holders
Holding Since
Mar 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ELVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cormorant Asset Management, LP holds $1,889,506,429 across 46 Biotechnology names. ELVN ranks #34 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PRAX |
Praxis Precision Medicines, Inc.
|
640,000 | $214,265,600 | |
| 2 | BBOT |
BridgeBio Oncology Therapeutics, Inc.
|
17,878,594 | $136,234,886 | |
| 3 | PBLS |
Parabilis Medicines, Inc.
|
4,615,612 | $126,329,300 | |
| 4 | RAPP |
Rapport Therapeutics, Inc.
|
2,657,521 | $110,738,900 | |
| 5 | ERAS |
Erasca, Inc.
|
6,000,000 | $109,920,000 | |
| 6 | EWTX |
Edgewise Therapeutics, Inc.
|
2,510,000 | $101,981,300 | |
| 7 | EYPT |
EyePoint, Inc.
|
7,000,000 | $100,100,000 | |
| 8 | ALMS |
Alumis Inc.
|
3,285,596 | $92,456,671 |
All Filings in ELVN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,612,500 | 150,000 | Shares | Defined | 2026-08-14 | |
| 2025-09-30 | $4,094,000 | 200,000 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $4,012,000 | 200,000 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $4,920,000 | 250,000 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $5,625,000 | 250,000 | Shares | Defined | 2025-02-14 | |
| 2023-09-30 | $16,620,285 | 1,216,712 | Shares | Defined | 2023-11-14 | |
| 2023-06-30 | $39,516,474 | 1,936,133 | Shares | Defined | 2023-08-14 | |
| 2023-03-31 | $42,401,312 | 1,936,133 | Shares | Defined | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||